Tenet Healthcare (THC) opened 2026 with Q1 results that build on a solid run of recent quarters, with trailing 12 month revenue of about US$21.3b and basic EPS of US$15.61 against a current share price around US$177. Revenue has moved from US$20.7b to US$21.3b on a trailing basis, while trailing net income excluding extra items has shifted from US$3.2b to US$1.4b. The latest print therefore lands in a context of steady top line and tighter earnings, setting up a quarter where investors will focus squarely on how margins are holding up.

See our full analysis for Tenet Healthcare.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the prevailing narratives around Tenet Healthcare, including what the community and analysts have been expecting and where those views might now be challenged.

Margins Squeezed as Net Profit Margin Drops to 6.6%

• Trailing net profit margin now sits at 6.6%, compared with 15.5% a year earlier, while trailing 12 month net income excluding extra items is US$1.4b on US$21.3b of revenue.
• Bears argue that margin pressure could be a sign that higher acuity and better payer mix are doing less heavy lifting than before, and the move from a 15.5% margin to 6.6% lines up with that concern. Bullish investors point to high margin outpatient platforms such as USPI and recent cost control efforts as potential supports that are not yet fully visible in the latest trailing numbers.
  • Bearish commentary highlights the risk that improvements in payer mix and patient acuity may not continue at past rates, while the current margin profile already reflects a meaningful gap to last year.
  • Bullish arguments lean on investments in ambulatory centers and digital tools to improve efficiency, yet the current 6.6% margin shows that any expected benefits still have to contend with wage pressure and reimbursement dynamics that are already in the figures.

On a margin picture like this, skeptics point to the sharp gap between last year and today as evidence that mix and cost levers might not offset all the pressure they worry about, even as management actions aim in that direction. It is worth reading how cautious investors frame that argument in the 🐻 Tenet Healthcare Bear Case.

Revenue Growth at 3.2% Trails 11.1% Market Benchmark

• Over the last 12 months, revenue has grown about 3.2% while the cited US market benchmark sits at 11.1%, with quarterly revenue in the period running between US$5.1b and US$5.5b.
• Supporters of the bullish view see opportunities in outpatient growth and broader insurance coverage. However, the 3.2% trailing growth rate compared with the 11.1% benchmark and a forecast earnings decline of about 2.3% per year over the next three years shows that the current revenue trend and expected profit path still sit below what bullish volume and mix stories alone might suggest.
  • Bullish commentary points to higher acuity outpatient procedures and expanding exchange admissions as drivers of demand, while the actual trailing growth rate remains well behind the overall market benchmark.
  • Forecasts in the data calling for around 2.3% annual earnings decline sit uneasily next to bullish expectations for higher margins and higher earnings by 2029, which would require the growth drivers to translate into stronger profitability than the recent figures imply.

This mix of modest trailing growth and cautious multi year earnings forecasts sets up an interesting test of the optimistic storyline, and it is useful to see exactly how bullish investors connect the dots between today’s numbers and their 2029 assumptions in the 🐂 Tenet Healthcare Bull Case.

P/E of 11.2x and DCF Fair Value of US$635.77 vs US$177 Price

• The shares trade on a trailing P/E of 11.2x, compared with a 24.3x industry average and 20.9x peer average, and against a DCF fair value of about US$635.77 and an analyst price target of about US$261.48 versus the current share price around US$177.12.
• What stands out is how strongly the valuation gap supports bulls at the same time as margin and earnings trends give bears material points to work with. Earnings over the most recent year were negative, net margin has moved from 15.5% to 6.6%, yet the shares sit well below the DCF fair value and below the cited analyst target, so investors are weighing discounted multiples against weaker recent profitability and multi year earnings decline forecasts.
  • Bears highlight the high level of debt and pressure on margins as reasons the discount might persist, particularly if the forecast 2.3% annual drop in earnings plays out.
  • Bulls point to the large gap between the P/E of 11.2x and both the industry averages and the DCF fair value of US$635.77 as evidence the market may already be pricing in a lot of that caution, while analyst targets in the data indicate upside from the current US$177.12 level.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Tenet Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between pressure on margins and a sizeable valuation gap, now is a good time to weigh the trade offs yourself and see how they stack up against the 3 key rewards and 4 important warning signs.

See What Else Is Out There

Tenet Healthcare is working with squeezed margins, slower 3.2% revenue growth than the 11.1% market benchmark, and forecasts pointing to an earnings decline.

If you are concerned about that mix of margin pressure and a soft earnings outlook, you may want to compare it with companies showing stronger value signals by checking out the 51 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.